Applied DNA Sciences Files 8-K with Bylaw Amendments
Ticker: BNBX · Form: 8-K · Filed: Nov 7, 2024 · CIK: 744452
Sentiment: neutral
Topics: corporate-governance, filing, financials
Related Tickers: APDN
TL;DR
APDN filed an 8-K for bylaw changes and exhibits - check for governance shifts.
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on November 7, 2024, reporting amendments to its Articles of Incorporation or Bylaws and submitting financial statements and exhibits. The company, incorporated in Delaware, operates in the testing laboratories sector and is headquartered in Stony Brook, NY.
Why It Matters
This filing indicates potential changes in the company's governance or operational structure, which could impact its strategic direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and financial information, not indicating immediate financial distress or significant operational shifts.
Key Numbers
- 001-36745 — SEC File Number (Identifies the company's filing history with the SEC.)
- 59-2262718 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Stony Brook, NY (location) — Business address
- 8734 (sic_code) — Standard Industrial Classification for Testing Laboratories
FAQ
What specific amendments were made to the Articles of Incorporation or Bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary information; they would be found within the attached exhibits.
What financial statements and exhibits are included with this 8-K filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these documents is not detailed in the provided summary.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on November 7, 2024.
What is Applied DNA Sciences, Inc.'s Standard Industrial Classification (SIC) code?
Applied DNA Sciences, Inc.'s SIC code is 8734, which corresponds to Testing Laboratories.
What is the company's fiscal year end?
The company's fiscal year ends on September 30.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-07 16:30:23
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm2427797d1_8k.htm (8-K) — 27KB
- tm2427797d1_ex3-1.htm (EX-3.1) — 7KB
- 0001104659-24-115342.txt ( ) — 205KB
- apdn-20241107.xsd (EX-101.SCH) — 3KB
- apdn-20241107_lab.xml (EX-101.LAB) — 33KB
- apdn-20241107_pre.xml (EX-101.PRE) — 22KB
- tm2427797d1_8k_htm.xml (XML) — 4KB
03. Amendments to Articles of Incorporation or
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 7, 2024, the board of directors of Applied DNA Sciences, Inc. (the "Company") adopted a certificate of amendment (the "Certificate of Amendment") to its bylaws (the "Bylaws"). Also on November 7, 2024, a duly authorized officer of the Company executed the Certificate of Amendment, which became effective upon execution. Among other things, the Certificate of Amendment amended the Bylaws to: Reduce the required quorum for any meeting of stockholders to one-third (1/3) of the issued and outstanding shares entitled to vote at a meeting from a majority of the issued and outstanding shares entitled to vote at a meeting; and Grant the Chief Executive Officer of the Company the authority to adjourn any meeting of stockholders of the Company. The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment to the Bylaws, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Bylaws 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 7, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer